Vimarsana
Biggest News Aggregation in the World

Chiron Behring News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Chiron Behring. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Chiron Behring Today - Breaking & Trending Today

Medigene : CV Dr. Gerd Zettlmeissl - MarketScreener - Vimarsana News

Medigene : CV Dr. Gerd Zettlmeissl - MarketScreener

Annual general meeting of Medigene AG on 24 June 2024 Convenience Translation Gerd Zettlmeissl, PhD ...

Covaxin maker Bharat Biotech, linked firms gave Rs 25 crore to TDP even though it is out of power - Vimarsana News

Covaxin maker Bharat Biotech, linked firms gave Rs 25 crore to TDP even though it is out of power

Some believe it is because of the professional and personal relationships between members of the Kamma community.

Source: scroll.in
Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152) - Vimarsana News

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

MALVERN, Pa., Feb. 18, 2022 -- Ocugen, Inc. , a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the... | February 18, 2022

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety - Vimarsana News

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS - Vimarsana News

Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data From COVAXIN™ (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS

National Institute of Virology . COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. With more than 125 million doses having... | December 30, 2021